
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a clinical-stage biopharmaceutical company that has a positive outlook due to its suite of therapeutic platforms and fully integrated drug development engine, which allows for precise engineering of differentiated therapeutic product candidates. The company's lead clinical candidate, zanidatamab, is currently being evaluated in multiple clinical trials and has shown promising results. The company's pivot to a core royalty aggregation model, with potential partnerships for its programs, as well as its differentiated royalty creation strategy, also contribute to its positive outlook. However, clinical trial risk remains a key concern as the company's valuation is highly dependent on the success of its pipeline assets.
Bears say
Zymeworks is currently facing numerous challenges including clinical trial failures, commercial and biotech sector risk, and financing risks due to its capital-intensive nature. A recent financing deal with Royalty Pharma and positive clinical trial results for its candidate drug zanidatamab may provide some short-term benefits, but overall, the company's lack of differentiation and uncertainties surrounding its pipeline pose long-term concerns and warrant a negative outlook on its stock.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares